Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 8 | 2024 | 329 | 1.570 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 4 | 2024 | 226 | 1.120 |
Why?
|
| Tuberculosis | 5 | 2023 | 543 | 0.990 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2024 | 324 | 0.950 |
Why?
|
| Sensitivity and Specificity | 13 | 2024 | 385 | 0.910 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 284 | 0.820 |
Why?
|
| Immunoassay | 2 | 2022 | 28 | 0.760 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 56 | 0.690 |
Why?
|
| Molecular Diagnostic Techniques | 6 | 2024 | 132 | 0.620 |
Why?
|
| Isoniazid | 5 | 2024 | 110 | 0.520 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 231 | 0.480 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2024 | 198 | 0.460 |
Why?
|
| Rifampin | 4 | 2024 | 197 | 0.460 |
Why?
|
| Humans | 16 | 2024 | 14537 | 0.300 |
Why?
|
| Point-of-Care Testing | 3 | 2022 | 71 | 0.260 |
Why?
|
| Cancer Vaccines | 1 | 2023 | 1 | 0.210 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2022 | 35 | 0.190 |
Why?
|
| World Health Organization | 1 | 2022 | 137 | 0.190 |
Why?
|
| Feasibility Studies | 1 | 2022 | 101 | 0.190 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 24 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 39 | 0.180 |
Why?
|
| Immunologic Tests | 1 | 2020 | 7 | 0.170 |
Why?
|
| Biological Assay | 1 | 2020 | 32 | 0.170 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2021 | 303 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 56 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2020 | 167 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
| Feces | 1 | 2018 | 30 | 0.150 |
Why?
|
| Adult | 7 | 2024 | 5913 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 59 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.140 |
Why?
|
| Genotyping Techniques | 1 | 2017 | 38 | 0.130 |
Why?
|
| Male | 7 | 2024 | 6754 | 0.130 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2018 | 195 | 0.130 |
Why?
|
| Aged | 4 | 2022 | 1740 | 0.120 |
Why?
|
| South Africa | 7 | 2024 | 7596 | 0.120 |
Why?
|
| Middle Aged | 5 | 2022 | 3601 | 0.120 |
Why?
|
| Female | 7 | 2024 | 9103 | 0.120 |
Why?
|
| Mycobacterium | 1 | 2015 | 16 | 0.120 |
Why?
|
| Coinfection | 1 | 2017 | 276 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 54 | 0.110 |
Why?
|
| Young Adult | 4 | 2022 | 2498 | 0.100 |
Why?
|
| HIV Infections | 3 | 2020 | 5097 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 135 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2022 | 150 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 468 | 0.080 |
Why?
|
| Nasopharynx | 2 | 2022 | 151 | 0.080 |
Why?
|
| Sputum | 2 | 2021 | 135 | 0.080 |
Why?
|
| Specimen Handling | 2 | 2020 | 105 | 0.070 |
Why?
|
| Adolescent | 3 | 2020 | 2985 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2021 | 1160 | 0.060 |
Why?
|
| Moldova | 1 | 2024 | 3 | 0.060 |
Why?
|
| India | 1 | 2024 | 62 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 44 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 42 | 0.050 |
Why?
|
| Capreomycin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Kanamycin | 1 | 2021 | 5 | 0.050 |
Why?
|
| Ethionamide | 1 | 2021 | 9 | 0.050 |
Why?
|
| Amikacin | 1 | 2021 | 7 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 48 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2021 | 20 | 0.050 |
Why?
|
| Prognosis | 1 | 2022 | 199 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2024 | 322 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 370 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 109 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 217 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2022 | 799 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 29 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 967 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1422 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 656 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 49 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 179 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 1748 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 442 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 2244 | 0.020 |
Why?
|